Physician profile
Sam Moskowitz
NPI 1851377394
$332,142.37
in general payments reported to CMS, 2019-2025
37 companies · $96K in 2025
The $96K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $19K · 2021: $24K · 2022: $42K · 2023: $36K · 2024: $66K · 2025: $96K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $142K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $20K · Travel and Lodging: $14K · Food and Beverage: $13K · Consulting Fee: $8,350 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $141,572.72 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $20,425.00 |
| Travel and Lodging | $13,746.64 |
| Food and Beverage | $13,366.32 |
| Consulting Fee | $8,350.00 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $128,245.79 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57,018.48 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Pfizer INC. | $32,235.93 | 2019-2025 | |
| Gilead Sciences, INC. | $31,797.32 | 2019-2025 | |
| Janssen Biotech, INC. | $30,922.85 | 2019-2025 | Tremfya, Stelara |
| Lilly USA, LLC | $26,785.78 | 2024-2025 | Omvoh, Zepbound |
| Phathom Pharmaceuticals, INC. | $8,973.16 | 2023-2025 | Voquezna |
| Eli Lilly and Company | $5,900.13 | 2024-2025 | Omvoh |
| Redhill Biopharma INC. | $3,183.69 | 2020-2025 | Talicia |
| Ardelyx, INC. | $1,504.77 | 2022-2025 | Ibsrela |
| Intuitive Surgical, INC. | $886.47 | 2019 | |
| Ironwood Pharmaceuticals, INC | $768.06 | 2019-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $688.43 | 2019-2025 | Entyvio |
| Celgene Corporation | $681.45 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $467.50 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $240.47 | 2021-2024 | Zeposia |
| Evoke Pharma, INC. | $235.00 | 2022 | |
| Concordia Pharmaceuticals INC. | $228.26 | 2019 | |
| Novo Nordisk INC | $212.90 | 2023-2025 | Ozempic, Rybelsus |
| Regeneron Healthcare Solutions, INC. | $181.86 | 2023-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $175.93 | 2020-2023 | Ocaliva |
| Allergan, INC. | $142.14 | 2019 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2020 | |
| Braintree Laboratories, INC. | $121.10 | 2019-2023 | Sutab |
| Merck Sharp & Dohme LLC | $76.37 | 2019-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $55.77 | 2020-2022 | |
| Intra-Sana Laboratories | $50.00 | 2023 | Glycate |
| Romark Laboratories, Lc | $45.21 | 2019 | |
| Celltrion USA INC. | $37.66 | 2025 | Vegzelma |
| Boston Scientific Corporation | $33.56 | 2022 | |
| Csl Behring | $22.52 | 2022 | |
| Glaxosmithkline, LLC. | $20.83 | 2019 | |
| Shionogi INC | $19.39 | 2019 | |
| Endo Pharmaceuticals INC. | $19.21 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $14.98 | 2025 | Iqirvo |
| Alfasigma USA, INC. | $13.30 | 2021 | |
| Daiichi Sankyo INC. | $11.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Moskowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.